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Abstract
The main goal of the current work was to develop and validate an in vitro fluke
egg hatch test, as a method for the detection of albendazole (ABZ) resistance
in the liver fluke, Fasciola hepatica. Fluke eggs (200/ml, n ¼ 5) from six different
isolates were used in the current experimental work. They were obtained
from different geographical locations and named Cullompton (UK), CEDIVE
(Chascomus, Argentina), INTA-Bariloche (Bariloche, Argentina), Rubino
(Uruguay), Cajamarca (Peru´) and Rı´o Chico (Catamarca, Argentina). The fluke
eggs were incubated (258C) for a 12-h period in the presence of either ABZ or its
sulphoxide metabolite (ABZ.SO) (5, 0.5 or 0.05 nmol/ml). Untreated eggs were
incubated as a control. Incubated eggs (with or without drug present) were kept
in darkness at 258C for 15 days. Afterwards, the trematode eggs were exposed to
daylight over a 2-h period. Hatched and unhatched eggs were evaluated using an
optical microscope, and the ovicidal activity was assessed for each fluke isolate.
A very low ovicidal activity (#13.4%) was observed in the ABZ-resistant
CEDIVE isolate for both ABZ and ABZ.SO. Conversely, in the INTA-Bariloche
and Rı´o Chico isolates, which are suspected to be susceptible to ABZ, ovicidal
activities $ 70.3% were observed after incubation with ABZ at the lowest
concentration tested (0.05 nmol/ml). This finding correlates with that previously
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described for the ABZ-susceptible Cullompton. Finally, the Cajamarca and
Rubino isolates behaved as ABZ resistant, since no ovicidal activity was observed
after eggs were incubated with ABZ at 0.5 nmol/ml. Considering the specific
results obtained for each isolate under assessment, the egg hatch test described
here may be a suitable method for detection of ABZ resistance in F. hepatica.
Introduction
Fasciolosis, caused by the trematode liver fluke, Fasciola
hepatica, is the cause of considerable losses in sheep and
cattle production systems all over the world (Fairweather,
2005). Fasciolosis is also emerging as a major zoonosis
(Mas Coma et al., 2005) and is considered to be a serious
health problem in some countries (Fairweather, 2005).
There are a limited number of anthelmintics available to
treat fasciolosis in ruminants. Benzimidazoles (BZD) are
broad-spectrum anthelmintic compounds, widely used in
human and veterinary medicine for controlling nema-
tode, cestode and trematode infections (McKellar &
Scott, 1990). The BZD compounds, currently marketed
as anthelmintics, can be grouped as BZD thiazolyls, BZD
methylcarbamates, pro-BZD and halogenated BZD thiols
(Lanusse & Prichard, 1993). Only a few BZD compounds
display activity against F. hepatica. The halogenated
derivative triclabendazole (TCBZ) is the most effective,
because of its excellent activity against immature and
mature adult flukes (Boray et al., 1983). Albendazole
(ABZ) is the only BZD methylcarbamate recommended
for the control of fasciolosis in domestic animals, despite
its activity being restricted to flukes older than 12 weeks
(McKellar & Scott, 1990). ABZ is not found in the
bloodstream after its enteral administration to sheep
(Marriner & Bogan, 1980) and cattle (Prichard et al., 1985).
ABZ oxidations lead to more polar and less active
metabolites, which are detected systemically as the
sulphoxide (ABZ.SO) and sulphone (ABZ.SO2) deriva-
tives. In terms of binding to Haemonchus contortus
b-tubulin, ABZ is more potent than the active ABZ.SO,
while ABZ.SO2 is an inactive metabolite (Lacey, 1990;
Lubega & Prichard, 1991).
The intensive use of TCBZ in endemic areas of
fasciolosis has resulted in the development of liver
fluke populations resistant to this compound (Overend
& Bowen, 1995; Moll et al., 2000; Thomas et al., 2000;
Olaechea et al., 2011a, b; Ortiz et al., 2011), which is
considered a major problem for veterinary therapeutics.
Interestingly, ABZ has been shown to be effective
against the TCBZ-resistant fluke isolate named Sligo
(Coles & Stafford, 2001; Fairweather, 2011a). Conversely,
a F. hepatica isolate resistant to ABZ and susceptible
to TCBZ has recently been characterized (Sanabria
et al., 2013).
The emergence of drug-resistant liver flukes leads to
the necessity of accurate diagnosis. The standard and
established protocol for the determination of drug activity
against F. hepatica in ruminants is the efficacy controlled
test (Wood et al., 1995), in which efficacy is determined by
comparison of the number of flukes in treated animals
and in untreated controls. This methodology has the
disadvantage of its relative high cost and the length of
time involved. The alternative is the use the faecal egg
count reduction test (FECRT), where the efficacy of the
treatment (or the susceptibility of the F. hepatica isolate) is
claimed if a 95% or greater reduction of faecal fluke egg
counts at 14 days post-treatment is achieved. However,
the release of eggs stored in the gall bladder may produce
false-positive results, even when the flukes have been
effectively removed by drug treatment (Fairweather,
2011b). The coproantigen reduction test (Flanagan
et al., 2011a, b) and the ‘histological approach’ (Hanna
et al., 2010, 2013), which involves the evaluation of the
histological changes induced by drug treatment, have
been proposed as alternative methods for the diagnosis of
drug efficacy and/or resistance. The egg hatch test may
have some potential to detect anthelmintic resistance in
flukes. This test, used as a diagnostic method for the
detection of BZD resistance in nematodes (Coles et al.,
2006), is based on the capacity of BZD compounds,
mainly the methylcarbamates, to affect parasite egg
hatching. Previously, it has been shown under in vitro
conditions that both ABZ and ABZ.SO have an excellent
ovicidal activity against F. hepatica eggs (Coles & Briscoe,
1978; Alvarez et al., 2009). Thus, an egg hatch-based
method potentially may be used for the detection of BZD
resistance in F. hepatica. Using a high concentration of the
TCBZ sulphoxide metabolite, the test has the potential to
distinguish between TCBZ-susceptible and TCBZ-resist-
ant fluke isolates, and may become a simple method of
diagnosis of drug resistance (Fairweather et al., 2012).
However, the use of such a methodology to detect ABZ
resistance in liver flukes requires further investigation.
The main goal of the work reported here was to develop
and validate an in vitro fluke egg hatch test, for the
detection of ABZ resistance in F. hepatica. The test was
applied to assess ABZ ovicidal activity in fluke isolates
obtained from different sources.
Materials and methods
Pure ($99%) reference standards of ABZ and ABZ.SO
used in the current test were provided by Toronto
Research Chemicals Inc. (Toronto, Canada). The solvent
(methanol) used for drug dissolution was of analytical
grade (Anedra, Buenos Aires, Argentina). Fasciola hepatica
eggs from six different isolates were assessed for
ABZ/ABZ.SO susceptibility. Two of them (CEDIVE and
Cullompton) were considered to be Reference isolates,
while the others were considered to be Unknown isolates.
Unfortunately, at the time of the egg hatch test
development there were no eggs from the Cullompton
isolate available in our laboratory. Since the egg hatch test
previously published (Alvarez et al., 2009) was performed
under similar experimental conditions as in the current
study, the data relating to the inhibition of egg hatching
of the Cullompton isolate by ABZ was included as a
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‘positive control’. Details of the different isolates with
regard to ABZ susceptibility are given below.
Reference isolates
CEDIVE
This isolate was obtained from the bile ducts of two
sacrificed sheep, and subsequently maintained in donor
sheep and Lymnaea viatrix snails under laboratory
conditions at the ‘Centro de Diagno´stico e Investigaciones
Veterinarias’ (CEDIVE), Facultad de Ciencias Veterinar-
ias, Universidad Nacional de La Plata, Chascomu´s,
Argentina. After two controlled efficacy tests, this isolate
has been shown to behave as resistant to ABZ and
susceptible to TCBZ (Sanabria et al., 2013).
Cullompton
This isolate was first obtained (1998) from sheep
slaughtered at an abbatoir in Cullompton, Devon, UK,
and has been maintained in Queens University, Belfast,
UK since 1999 (Fairweather, 2011a). In different in vivo
and in vitro studies, the Cullompton isolate has been
shown to be susceptible to TCBZ (Walker et al., 2004;
McConville et al., 2009, Devine et al., 2010, 2012; Toner
et al., 2010; Flanagan et al., 2011b) and ABZ (Buchanan
et al., 2003; McConville et al., 2006; Alvarez et al., 2009).
Unknown isolates
INTA-Bariloche
This isolate was obtained from naturally infected
cattle on a Patagonian farm in Neuque´n, Argentina, by
Dr Fermı´n Olaechea (INTA Bariloche, Bariloche, Argen-
tina). Resistance to TCBZ has been determined by the
faecal egg count reduction test (FECRT) (Olaechea et al.,
2011a) and confirmed after TCBZ treatment of artificially
infected sheep (Olaechea et al., 2011b). The INTA-Bariloche
isolate has been maintained under the same laboratory
conditions as described for the CEDIVE isolate. No
definitive data are available regarding potential suscepti-
bility to ABZ. However, two sheep artificially infected with
this isolate and orally treated with ABZ (7.5 mg/kg) 16
weeks after infection, became negative to F. hepatica eggs in
the faeces (L. Alvarez, unpublished data), indicating its
potential susceptibility to ABZ.
Rubino
This isolate was obtained from naturally infected
sheep from a farm near Salto, Uruguay, and has been
maintained under laboratory conditions at the DILAVE
Laboratory, Montevideo, Uruguay. According to its
previous history, this isolate is susceptible to closantel
and nitroxynil, but there is no definitive information on
ABZ susceptibility. However, F. hepatica eggs were
recovered from faeces obtained from two sheep artifi-
cially infected with the Rubino isolate, 15 days post-ABZ
oral treatment (7.5 mg/kg) (V. Gayo, unpublished data).
Cajamarca
This isolate was obtained from faeces collected from one
cow on a farm located in Cajamarca, Peru´, and has been
maintained under laboratory conditions at the Laboratorio
de Diagno´stico Veterinario, Facultad de Ciencias Veter-
inarias, Universidad Nacional de Cajamarca, Cajamarca,
Peru´. This isolate behaves as TCBZ resistant (Ortiz et al.,
2011). No data are available on ABZ susceptibility.
However, in the area where the isolate was recovered,
the frequent use of different anthelmintics (including
ABZ) to control trematode and nematode infections is a
common practice.
Rı´o Chico
Eggs from this isolate were recovered from one sheep
sacrificed at a local abattoir in the area of Rı´o Chico,
Catamarca, Argentina. No data on potential susceptibi-
lity/resistance to anthelmintics of this isolate has been
obtained. However, since no type of anthelmintic
treatment is performed at the farm where the sheep
were bred, it is highly likely that the Rio Chico isolate is
susceptible to all flukicidal compounds, including ABZ.
In vitro egg hatch test
The in vitro egg hatch test used in the current
experiment was previously described by Alvarez et al.
(2009). Briefly, fluke eggs (200 eggs in 1 ml of water placed
in Khan tubes) from each isolate (each isolate represents
one experiment) were incubated (258C) for a 12-h period
with either ABZ or ABZ.SO, at a final concentration
of 5, 0.5 or 0.05 nmol/ml. These are pharmacologically
relevant concentrations obtained from previous studies
where the bile concentrations of these compounds were
measured after conventional treatments in sheep (Hen-
nessy et al., 1989; Alvarez et al., 2000). The working
solutions of pure ABZ and ABZ.SO were prepared by
dissolution in acidified methanol at final concentrations
of 500, 50 and 5 nmol/ml. Ten microlitres of each working
solution was added to 1 ml of egg suspension (methanol
concentration: 1%). In each experiment, five replicates
were used for each drug concentration. Control eggs were
incubated with the solvent (without drug). The low
number of F. hepatica eggs recovered from the Bariloche
and Rubino isolates prevented their incubation with
ABZ.SO. Untreated and treated eggs were gently washed
with tap water (3 £ ) to facilitate drug removal, and kept
in darkness at 258C for 15 days. After this period, the
trematode eggs were exposed to daylight for 2 h.
Immediately afterwards, 1 ml of 10% (v/v) buffered
formalin was added to each tube in order to prevent
further eggs from hatching. Hatched and unhatched
eggs were evaluated using an optical microscope (40 £
magnification). Approximately 80–90 eggs were counted
in order to estimate the proportion of hatched eggs in
each tube. The ‘ovicidal activity’ expressed as a
percentage was estimated using the following formula:
Ovicidal activity ð%Þ ¼ ½ð% eggs hatched in control
2% eggs hatched after drug
incubationÞ=% eggs hatched
in control £ 100
The percentages of egg hatch are reported as the
arithmetic mean ^ standard deviation (SD). Parametric
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analysis of variance plus Tukey’s test were used for the
statistical comparison of the egg hatch data obtained from
each experiment. A value of P , 0.05 was considered
statistically significant. The statistical analysis was
performed using the Instat 3.0 Software (Graph Pad
Software, California, USA).
Results
The mean egg hatch percentage obtained for untreated
eggs in the different F. hepatica isolates ranged between
67.0 (CEDIVE) and 94.8% (Rı´o Chico) (table 1). ABZ
affected egg hatch in the Cullompton, INTA-Bariloche
and Rı´o Chico isolates at all concentrations tested.
Conversely, ABZ (at 5, 0.5 and 0.05 nmol/ml) did not
affect egg hatch in the CEDIVE isolate. A similar
behaviour after ABZ incubation was observed in the
Rubino and Cajamarca isolates, in which egg hatch was
inhibited only at the highest concentration of 5 nmol/ml
but, at lower concentrations (0.5 and 0.05 nmol/ml),
the drug failed to inhibit hatching. In the Cullompton
and Cajamarca isolates, the reduction in egg hatch with
ABZ.SO was lower than that observed for ABZ.
A very low ovicidal activity (#13.4%) was observed
in the ABZ-resistant CEDIVE isolate for both ABZ
parent compound and its sulphoxide metabolite, even
at the highest concentration tested (5 nmol/ml) (fig. 1).
Conversely, in the INTA-Bariloche and Rı´o Chico
isolates, suspected to be susceptible to ABZ, ovicidal
activities $ 70.3% were observed after incubation with
ABZ at the lowest concentration tested (0.05 nmol/ml)
(fig. 1). This finding correlates with that previously
described for the ABZ-susceptible Cullompton isolate
(Alvarez et al., 2009). Finally, in the Cajamarca and Rubino
isolates, no ovicidal activity was observed after incu-
bation of eggs with ABZ at 0.5 nmol/ml (fig. 1).
Discussion
In ABZ-susceptible F. hepatica isolates, such as the
Cullompton isolate, ABZ showed excellent ovicidal
activity (Alvarez et al., 2009), even at concentrations
as low as 0.05 nmol/ml (fig. 1). In this isolate, a high
ovicidal efficacy was also observed for the active
ABZ.SO metabolite, in spite of its lower anthelmintic
potency compared to the parent drug. However, in the
well-characterized ABZ-resistant CEDIVE isolate
(Sanabria et al., 2013), both ABZ and ABZ.SO failed to
prevent the egg hatch, demonstrating that the method is
suitable to detect ABZ resistance in F. hepatica. It is
important to highlight that in the ABZ-resistant CEDIVE
isolate, egg hatching was not inhibited, even at the highest
ABZ/ABZ.SO concentration tested (5 nmol/ml) (fig. 1).
Regarding the ‘Unknown isolates’, the INTA-Bariloche
isolate showed susceptibility to ABZ in the in vitro
test, with ovicidal activities ranging between 71.2%
(0.05 nmol/ml) and 96.4% (5 nmol/ml) (fig. 1). This is a
TCBZ-resistant isolate (Olaechea et al., 2011a, b), obtained
from a farm where all anthelmintic treatments used in
cattle are mainly directed against the liver fluke (and
involve TCBZ and closantel), with sporadic treatment of
gastrointestinal nematodes using ivermectin. The lack
of a BZD methylcarbamate selection pressure may help to
explain the potential susceptibility of the INTA-Bariloche
isolate to ABZ observed in the current work. It may
be assumed that the INTA-Bariloche isolate behaves
in a similar way to the Sligo isolate, which has been
previously characterized as resistant to TCBZ and
susceptible to ABZ (Coles & Stafford, 2001). The present
in vitro finding was partially validated by an in vivo
study in which two sheep, artificially infected with this
isolate, were treated with ABZ (7.5 mg/kg) 16 weeks
after infection. There were no fluke eggs in the faeces
15 days after treatment, which would indicate a good
ABZ efficacy (L. Alvarez, unpublished data). Although
this in vivo trial is not definitive, the result may support
the usefulness of the in vitro method in detecting ABZ
resistance in liver flukes.
The Rio Chico isolate behaves as susceptible to ABZ
and/or ABZ.SO, since a marked (P , 0.05) egg hatch
reduction was observed at the three concentrations tested
compared to the untreated control (table 1). The ABZ
ovicidal activity ranged between 70.3% (0.05 nmol/ml)
and 84% (5 nmol/ml) (fig. 1). Similarly, the efficacy of
ABZ.SO ranged between 73.8% and 81.2%. Rı´o Chico is
located in the Catamarca province, Argentina, in a semi-
arid region where nematode parasites are not prevalent.
Table 1. Hatching of Fasciola hepatica eggs from different isolates, after incubation at 258C with either albendazole (ABZ) or ABZ
sulphoxide (ABZ.SO) at different concentrations for a 15-day period (with drug removal after a 12-h incubation). Values indicate
percentage of total incubated eggs, expressed as mean ^ SD.
Fasciola hepatica isolate
Drug concentration
(nmol/ml) Cullompton1 CEDIVE INTA- Bariloche Rı´o Chico Rubino Cajamarca
Control 0 72.6 ^ 4.1a 67.0 ^ 6.7a 73.2 ^ 4.5a 94.8 ^ 1.6a 87.4 ^ 6.2a 92.8 ^ 8.5a
ABZ 5 3.7 ^ 4.2b 58.0 ^ 11a 2.60 ^ 2.9b 15.2 ^ 6.3b 0.60 ^ 0.9b 8.80 ^ 4.6b
0.5 2.7 ^ 2.4b 67.4 ^ 9.3a 12.0 ^ 7.4b, c 17.4 ^ 11b 90.6 ^ 4.2a 89.4 ^ 5.7 a
0.05 13.2 ^ 6.2b 76.4 ^ 7.2a 21.1 ^ 9.5c 28.2 ^ 2.4b 90.0 ^ 2.7a 91.4 ^ 5.0a
ABZ.SO 5 4.6 ^ 3.0b 65.0 ^ 8.9a nd 22.8 ^ 10b nd 86.4 ^ 8.4a
0.5 20.2 ^ 7.5c 74.6 ^ 7.8a nd 17.8 ^ 3.5b nd 86.6 ^ 3.8a
0.05 58.4 ^ 10.7a 75.6 ^ 8.0a nd 24.8 ^ 7.7b nd 85.2 ^ 6.9a
For each fluke isolate, values with different superscripts are statistically different (P , 0.05). nd, not determined.
1Data obtained from Alvarez et al. (2009).
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Most farmers graze sheep under a very low density of
animals, and do not use anthelmintics in their sanitary
management. As a consequence, it is not surprising that
the isolate behaves as susceptible to ABZ. Interes-
tingly, the ovicidal activity against the Rı´o Chico isolate
appears to be slightly lower than that described for
the Cullompton isolate. Differences in drug suscepti-
bility between isolates have been described previously
(Fairweather, 2011a). For instance, the Cullompton isolate
is more sensitive to nitroxynil than either the Sligo,
Oberon or Fairhurst isolates (McKinstry et al., 2009),
which may be related to biological differences among the
fluke isolates (Walker et al., 2004).
Similar findings were observed after drug incubation
with F. hepatica eggs from the Cajamarca and Rubino
isolates. Interestingly, following incubation with ABZ at
the highest concentration (5 nmol/ml), both isolates
behave as susceptible to ABZ. Ovicidal efficacies were
90.5% (Cajamarca) and 99.3% (Rubino) (fig. 1). However,
at lower concentrations (#0.5 nmol/ml), the drug failed
to inhibit egg hatching, which suggests that these isolates
may be resistant to ABZ, but probably at a lower degree
than that observed for the CEDIVE isolate. Unfortunately,
this hypothesis could not be fully tested under in vivo
conditions. However, in a preliminary field efficacy trial,
F. hepatica eggs were recovered after ABZ treatment
(7.5 mg/kg) in two sheep artificially infected with the
Rubino isolate (V. Gayo, unpublished data). Although a
controlled efficacy test is needed to corroborate these
findings, the preliminary data described here may
demonstrate that flukes belonging to the Rubino isolate
may possess some degree of resistance to ABZ.
Concerning animal welfare, in vitro methods constitute
an alternative to clinical efficacy tests such as ‘dose and
slaughter’ trials (where a large number of animals need to
be infected and sacrificed after treatment). Egg collection
for this type of test could eventually be performed
directly from faecal material, making any animal sacrifice
unnecessary. The use of the egg hatch test as a tool to
detect ABZ resistance should be corroborated with in vivo
trials, in order to establish the in vitro/in vivo relationship,
and its applicability with eggs isolated from faecal
material (sheep and/or cattle) and from different animal
categories (that is, young animals, adult animals).
Therefore, the described in vitro egg hatch test appears
to be a suitable method for detection of ABZ resistance in
F. hepatica. The key reference ABZ concentration to be
used in the test appears to be 0.5 nmol/ml, assuming
susceptibility with efficacies $ 70% and resistance with
efficacies # 40% (fig. 1). The area between 40 and 70% of
egg hatch inhibition represents an area where resistance/
susceptibility would be suspected. The correct adjust-
ment of this ‘scale’ needs further research to be far more
conclusive. However, the data described here clearly
demonstrate the value of the egg hatch test as a suitable
method to detect ABZ resistance in F. hepatica.
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